NCT05155579View on ClinicalTrials.gov

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

593

Participants

Timeline

Start Date

May 14, 2022

Primary Completion Date

May 27, 2025

Study Completion Date

May 27, 2025

Conditions
Malaria
Interventions
BIOLOGICAL

R21/Matrix-M - single vial formulation

Adjuvanted malaria vaccine in a single vial formulation

BIOLOGICAL

R21/Matrix-M - two vial formulation

Adjuvanted malaria vaccine in a double vial formulation

BIOLOGICAL

Licensed vaccine - Measles-rubella

Licensed vaccine part of the EPI vaccination schedule

BIOLOGICAL

Licensed vaccine - Yellow fever

Licensed vaccine part of the EPI vaccination schedule

BIOLOGICAL

Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)

Licensed vaccine part of the EPI vaccination schedule

BIOLOGICAL

Licensed vaccine - Oral Polio Vaccine (OPV)

Licensed vaccine part of the EPI vaccination schedule

BIOLOGICAL

Licensed vaccine - Rotavirus

Licensed vaccine part of the EPI vaccination schedule

BIOLOGICAL

Licensed vaccine - Pneumococcal vaccine

Licensed vaccine part of the EPI vaccination schedule

BIOLOGICAL

Licensed vaccine - Inactivated Polio Vaccine (IPV)

Licensed vaccine part of the EPI vaccination schedule

Trial Locations (2)

Unknown

Malaria Research & Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako, Bamako

CCVTM, University of Oxford, Oxford

All Listed Sponsors
collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

lead

University of Oxford

OTHER